Healthcare, Pharma & Life Sciences

Compugen to Detail COM701 Ovarian Cancer Trial Data at Oct. 5 KOL Event

Image
Compugen to Detail COM701 Ovarian Cancer Trial Data at Oct. 5 KOL Event

Holon, Israel – September 22, 2026 -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) will host a virtual key opinion leader event on October 5, 2026 at 8:00 AM ET, presenting new detail on COM701, its anti-PVRIG antibody candidate for relapsed platinum-sensitive ovarian cancer (PSOC).

Harvard oncologist to preview MAIA-ovarian trial design and timeline

Oladapo Yeku, M.D., Ph.D., FACP, of Harvard Medical School and Massachusetts General Hospital, will join Compugen management to discuss the randomized MAIA-ovarian adaptive platform trial. The study evaluates COM701 as a maintenance therapy in relapsed PSOC patients, with median progression-free survival data from the interim analysis expected by Q1 2027. COM701 has already shown initial anti-tumor activity and a favorable safety and tolerability profile in Phase 1 studies as monotherapy and in combination regimens.

Edgewise Reveals EDG-7500 Data Targeting Novel Cardiac Muscle Protein

Image
Edgewise Reveals EDG-7500 Data Targeting Novel Cardiac Muscle Protein

Boulder, Colorado – September 22, 2026 -- Edgewise Therapeutics (Nasdaq: EWTX) disclosed preclinical data showing its lead cardiac drug candidate EDG-7500 improves heart relaxation while preserving systolic function, a mechanism the company says addresses a core driver of hypertrophic cardiomyopathy (HCM) that current therapies do not fully target.

Edgewise screened over 7,000 candidates to isolate a first-in-class RLC modulator

The company's Chief Scientific Officer, Alan Russell, said Edgewise screened more than 7,000 pharmacologically diverse compounds targeting the Regulatory Light Chain (RLC) before selecting molecules exhibiting positive lusitropic properties without compromising systolic performance. "EDG-7500's diastolic-biased profile has the potential to address a central pathologic driver of both symptomatic obstructive and nonobstructive HCM," Russell said.

SystImmune Wins FDA IND Clearance Using Non-Animal Test Methods

Image
SystImmune Wins FDA IND Clearance Using Non-Animal Test Methods

Redmond – September 22, 2026 -- SystImmune Inc. has secured U.S. Food and Drug Administration clearance for its Investigational New Drug application for SI-B037, a bispecific antibody, marking the first time the company has built a regulatory submission entirely on New Approach Methodologies (NAMs) rather than traditional animal toxicology studies.

SystImmune replaces animal testing with human organ-on-chip models

The IND package for SI-B037 relied on human organ-on-chip systems and primary human tissue models instead of conventional animal studies to assess nonclinical safety. Dr. Jahan Khalili, Senior Vice President of Research at SystImmune, said the human-relevant models provided a more direct read on a molecule engineered to engage multiple human pathways simultaneously.

Zocdoc Expands Booking Network to AI Platforms, Search Engines

Image
Zocdoc Expands Booking Network to AI Platforms, Search Engines

NEW YORK – September 22, 2026 -- Zocdoc announced a platform expansion that makes healthcare providers bookable beyond Zocdoc.com through a single connection to its Care Access Network, which already includes Amazon Health AI, Gemini, Yelp, Healthgrades, Blue Shield of California and multiple search engines.

Patients now search for care across a growing number of fragmented channels

A new national Zocdoc survey found that 69% of patients who search for a new doctor check multiple places, from AI platforms and insurance directories to search engines and review sites. More than 1 in 3 patients have switched doctors because scheduling was too difficult, while 43% would consider switching to a provider that is easier to book.

New $75.4M Trebinje Hospital Uses Crystalline Waterproofing on 6,500 m2 Roof

Image
New $75.4M Trebinje Hospital Uses Crystalline Waterproofing on 6,500 m2 Roof

Trebinje – – September 22, 2026 -- The newly completed Trebinje Hospital in Bosnia and Herzegovina represents a $75.4 million (€65 million / ≈128 million BAM) investment by the Government of Republika Srpska, marking the largest healthcare infrastructure project in eastern Herzegovina's recent history.

Facility spans 17,500 m2 with 223 beds and six operating rooms

Located in the Pridvorci neighborhood of Trebinje, a city of roughly 32,000 residents, the hospital was completed at the end of 2025. The 17,500 m2 facility includes advanced diagnostic equipment such as MRI and CT scanners, along with fully equipped emergency and intensive care units.

Essity to Report Q3 2026 Results October 22, CEO Kolsrud to Present

Stockholm – September 22, 2026 -- Essity will publish its interim report for the third quarter of 2026 on October 22 at approximately 07:00 CET, the hygiene and health company confirmed.

CEO and CFO to host live webcast at 09:00 CET

President and CEO Ulrika Kolsrud, together with EVP and CFO Fredrik Rystedt, will present the results via a live webcast and teleconference at 09:00 CET the same day. The session will remain available for on-demand viewing after the live broadcast concludes.

Dial-in access offered across three regions

Investors and analysts seeking to participate in the question-and-answer session can join via dedicated conference lines in the UK, the United States, and Sweden. Essity has instructed participants to call in ahead of the scheduled start and identify themselves as joining the "Essity" call.

Beactica Starts IND-Enabling Studies for Glioblastoma Drug BEA-17

Uppsala, Sweden – September 22, 2026 -- Beactica Therapeutics AB has initiated IND-enabling studies for BEA-17, a first-in-class oral degrader targeting the epigenetic regulators LSD1 and CoREST, moving the glioblastoma therapy toward first-in-human trials.

Beactica targets a cancer with 15-month median survival and no new treatment in over two decades

Glioblastoma remains the most common and aggressive primary brain tumour, with a median overall survival of approximately 15 months. Standard of care has stayed essentially unchanged for more than 20 years, and immunotherapies successful against other cancers have consistently failed against GBM's immunosuppressive tumour microenvironment.

PharmaResearch Launches REJURAN Skin Booster in Hungary

Image
PharmaResearch Launches REJURAN Skin Booster in Hungary

Budapest – September 22, 2026 -- South Korean biopharmaceutical company PharmaResearch officially launched its REJURAN portfolio of polynucleotide (PN)-based skin boosters in Hungary, marking its latest expansion move in Europe's aesthetic medicine market.

Symposium at Budapest museum draws 100 aesthetic medicine professionals

The launch event was held on September 14 at the Museum of Fine Arts, Budapest, marking REJURAN's first collaboration with the institution. Approximately 100 dermatologists, plastic surgeons and other aesthetic medicine specialists attended the symposium, which featured seven speakers from Korea, the Czech Republic, Slovakia and Hungary, including Korean key opinion leaders Dr. Hyun Jun Park and Dr. Kyu Ho Lee.

BoomRay Licenses Preclinical Radioligand Asset to Novartis for $900M

Suzhou – September 22, 2026 -- Boomray Pharmaceuticals Co., Ltd. has signed an exclusive global license agreement with Novartis Pharma AG for an undisclosed preclinical radioligand therapy (RLT) asset, with total deal value reaching up to USD 900 million.

Novartis secures rights to undisclosed preclinical oncology asset

Under the agreement, BoomRay will be eligible to receive an upfront payment plus development, regulatory, and sales milestone payments totaling up to USD 900 million. The Suzhou-based company will also earn royalties on future global net sales of the licensed program.

BCG: Women's Longevity Care Gap Worth $350 Billion Globally

Image
BCG: Women's Longevity Care Gap Worth $350 Billion Globally

Boston – September 22, 2026 -- Women in perimenopause or menopause represent an estimated $350 billion in unmet demand within the global longevity market, according to a new Boston Consulting Group (BCG) study covering roughly 1 billion women worldwide already spending on longevity products and services.

Women outspend every other demographic on longevity but remain equally dissatisfied

The BCG report, titled "The $350 Billion Longevity Mismatch in Women's Health," surveyed 10,608 people across 12 countries for the St. Moritz Longevity Forum. Women in perimenopause or menopause spend a median $84 a month on longevity interventions, compared with $68 for other women and $73 for men. Roughly a third of these women said they would spend $108 a month if a product or service delivered visible results.